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come in all studies has been the severity of objectively
determined arterial occlusive disease on initial evaluation.
Based on these studies, generalizations can be made on
the clinical outcomes affecting patients with claudication.
Intermittent claudication can develop in five different
ways— improvement, stabilization of the disease, worsen-
ing of the disease but with no revascularization required,
worsening of the disease with revascularization required,
and requirement of an amputation, usually after progres-
sion of disease.
We have previously analyzed mortality among 2777
patients with claudication.10 This present work is based on
a subset of the cohort reported in the previous work,
because we restricted the current analysis to patients hav-
ing serial follow-up of at least three studies during at least
a 2-year follow-up period. The current study, one of the
largest and longest of its kind, involves the analysis of
prospectively collected data to delineate the natural his-
tory of intermittent claudication and determine risk fac-
tors for the development of ischemic rest pain (IRP) and
ischemic ulceration (IU) among a male veteran cohort.
METHODS
We reviewed 28,000 lower-extremity vascular labora-
tory studies done between January 1983 and January
1998 at the Pittsburgh Veterans Administration (VA)
Medical Center, representing 4669 patients. After initial
referral to the laboratory, patients with claudication were
asked to return at intervals of 6 to 12 months regardless
of their clinical presentation. This was part of a strategy to
prospectively follow these patients. The criteria used to
identify patients with claudication have been previously
Despite extensive study of claudication, the natural
history of the disease is not fully known. Several large
studies conducted before the 1980s demonstrated that
intermittent claudication is a relatively benign process with
a low incidence of disease progression.1-4 These older
studies documented a cumulative 10-year amputation rate
of approximately 11% and improvement of distance in
most persons over time. However, a shortcoming in these
studies was patient inclusion based on symptoms alone
and without any objective evidence that leg pain was a
result of vascular disease. In contrast, studies done in the
1980s suggest a somewhat different picture for patients
with claudication.5-9 Although the reported amputation
rates were still low, 30% to 40% of patients had sympto-
matic and/or objective deterioration over time as mea-
sured by ankle-brachial index (ABI). In addition, reported
risk factors associated with disease progression in most of
these studies include tobacco use and diabetes mellitus.
However, the most important predictor of clinical out-
962
From the Division of Vascular Surgerya and the Division of General
Internal Medicine,b the University of Pittsburgh Medical Center and
Veterans Administration Medical Center.
Supported in part by a Veteran’s Administration Competitive Pilot Fund
grant.
Competition of interest: nil.
Presented at the Fifteenth Annual Meeting of The Eastern Vascular Society,
Washington, DC, May 4-6, 2001.
Reprint requests: Satish C. Muluk, MD, Assistant Professor of Surgery, A-
1011 PUH, 200 Lothrop St, Pittsburgh, PA 15213 (e-mail:
muluk@usa.net).
Copyright © 2001 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2001/$35.00 + 0 24/6/119749
doi:10.1067/mva.2001.119749
Natural history of claudication: Long-term serial
follow-up study of 1244 claudicants
Rainier Aquino, MD,a Christopher Johnnides, MD,a Michel Makaroun, MD,a Jeffrey C. Whittle, MD,b
Visala S. Muluk, MD,b Mary E. Kelley, PhD,b and Satish C. Muluk, MD,a Pittsburgh, Pa
Objective: The purpose of this study was to delineate the natural history of claudication and determine risk factors for
ischemic rest pain (IRP) and ischemic ulceration (IU) among patients with claudication.
Methods: We prospectively collected data on 1244 men with claudication during a 15-year period, including demo-
graphics, clinical risk factors, and ankle-brachial index (ABI). We followed these patients serially with ABIs, self-
reported walking distance (WalkDist), and monitoring for IRP and IU. We used Kaplan-Meier and proportional
hazards modeling to find independent predictors of IRP and IU.
Results: Mean follow-up was 45 months; statistically valid follow-up could be carried out for as long as 12 years. ABI
declined an average of 0.014 per year. WalkDist declined at an average rate of 9.2 yards per year. The cumulative 10-
year risks of development of IU and IRP were 23% and 30%, respectively. In multivariate analysis using several clinical
risk factors, we found that only DM (relative risk [RR], 1.8) and ABI (RR, 2.2 for 0.1 decrease in ABI) predicted the
development of IRP. Similarly, only DM (RR, 3.0) and ABI (RR, 1.9 for 0.1 decrease in ABI) were significant predic-
tors of IU.
Conclusion: This large serial study of claudication is, to our knowledge, the longest of its kind. We documented an aver-
age rate of ABI decline of 0.014 per year and a decline in WalkDist of 9.2 yards per year. Two clinical factors, ABI and
DM, were found to be associated with the development of IRP and IU. Our findings may be useful in predicting the
clinical course of claudication. (J Vasc Surg 2001;34:962-70.)
published.10 Briefly, both clinical and noninvasive criteria
were used to identify 2777 patients with claudication. This
cohort was also used in this analysis. We restricted the cur-
rent study to patients having at least three studies with a
minimum follow-up interval of 2 years between the first
and last study. These follow-up criteria were applied so
that the study would meet its objective of delineating the
long-term natural history of claudication. A total of 1244
patients met both the criteria for claudication and the cri-
teria for follow-up. Vascular laboratory nurses monitored
all 1244 patients for IU and IRP. We defined IU as any
form of pedal tissue loss that did not heal in 3 weeks. The
diagnosis of IRP was made on the basis of the following
criteria: (1) foot pain lasting at least 3 weeks; (2) pain
severe enough to wake the patient at night; and (3) relief
of pain with dependency. We were able to study serial pro-
gression of ABI among 1065 patients, after excluding
patients with calcified vessels and missing ABI informa-
tion. ABI was measured as the ratio between the ankle
pressure (using the higher of the pressures measured over
the dorsalis pedis and the posterior tibial artery) and the
higher of the two brachial pressures. Pressure was mea-
sured by inflating a blood pressure cuff to 220 and then
recording the value at which the distal Doppler signal
returns upon slow cuff deflation. Patients were also inter-
viewed before vascular laboratory testing and asked to
report the distance they could walk (WalkDist) in yards
before having to stop because of claudication. These data
were sufficient to allow serial analysis in 779 of the 1244
patients (the remaining 165 patients could not provide a
clear answer to this question).
Outcome events were extracted from the national
patient care database as well as hospital records. The
national VA database has been validated by studies showing
accuracy rates >95% by comparison with direct patient
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record review (described at the Web site www.virec.
research.med.va.gov). In the national database, revascular-
ization and amputation procedures are tracked for all VA
hospitals. This allowed us to track these outcomes wherever
they may have occurred in the VA system. However, revas-
cularization and amputation may be incomplete because of
the possibility of veterans undergoing some procedures out-
side the VA. Missing data across the database were relatively
Table I. Clinical and demographic characteristics
Variable
Age (y)* 64 (7)













Current smoker at study entry 57%
Hypertension†
No hypertension 54%
Hypertension, no drug therapy 3%







Fig 1. Kaplan-Meier event-free survival curves for the study cohort showing IU (triangles) and IRP (circles). For both
curves, the standard error of the mean is less than 10% of the value of the survival function up to a follow-up of 12 years.
Below the graph is shown the number of at-risk subjects at 0, 3, 6, 9, and 12 years.
infrequent, ranging from 0% for the most fully populated
field (patient identification) to 8% for the field with the
greatest proportion of missing data (pulse pressure). Our
analyses required Microsoft Access (Microsoft, Redmond,
Wash) for descriptive statistics and SAS (SAS institute, Cary,
NC) for Cox proportional hazards modeling, Kaplan-Meier
plots, and parametric modeling. In performing our analysis,
we used the baseline values (ie, the value obtained at the first
vascular laboratory study) of all clinical variables, except
where specified otherwise. β values and relative risk (RR)
were calculated using the proportional hazards model (β is
the natural logarithm of RR). For most of the continuous
variables (age, smoking pack-years, pulse pressure, systolic
pressure), the RR specifies the risk multiplier for a one-unit
increase in the variable. For the continuous variable ABI, the
β value and RR are shown for a 0.1-unit increase in ABI. In
the case of the dichotomous (yes/no) variables, the RR indi-
cates the increased RR associated with having the risk factor.
RESULTS
General demographics and clinical characteristics of
the patient cohort are seen in Table I. Cohort characteris-
tics include those typical of vascular patients—age, race,
smoking, and other cardiovascular risk factors. The mean
follow-up was 45 months, and the mean number of stud-
ies per patient was 5.2; statistically valid follow-up could
be carried out for as long as 12 years.
Minor and major amputations occurred with a 10-year
cumulative frequency of less than 10%. The 10-year cumula-
tive frequency of surgical revascularization was 18%. Kaplan-
Meier curves showing the occurrence of IRP and IU are
shown in Fig 1. The cumulative 10-year risks of development
of IU and IRP were 23% and 30%, respectively. We also
found that ABI declined an average of 0.014 per year. This
decline was slow but significantly different from zero (P <
.01). WalkDist declined at an average of 9.2 yards per year, a
rate that again was significantly different from zero (P < .01).
We next sought to delineate the factors that were asso-
ciated with progression to IU and IRP among our patient
cohort. Tables II and III depict the results of univariate
Cox proportional hazards modeling of a number of poten-
tial predictors for both outcomes. The three factors that
had significant predictive value for IRP were diabetes
requiring insulin therapy, lower ABI, and higher pack-
years of smoking. Lower ABI and diabetes requiring med-
ication (either insulin or oral hypoglycemic therapy) were
the only identified predictors for IU.
In the case of IU, because diet-controlled diabetes was
not a significant risk factor and because the risk ratios were
similar for diabetes requiring oral hypoglycemics and dia-
betes requiring insulin, it was clear that we should use the
composite variable diabetes requiring medication for mul-
tivariate analysis of IU. In the case of IRP, we found that
the results of multivariate analysis were very similar
whether we used diabetes requiring insulin or the com-
posite variable diabetes requiring medication. For the sake
of simplicity, we therefore chose to use the composite vari-
able diabetes requiring medication for the multivariate
analysis of both IU and IRP. Our multivariate analysis
showed that lower ABI and diabetes requiring medication
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Table II. Univariate analysis: IRP
Variable β RR (CI) P
Age (y) –0.019 0.981 (0.96, 1.00) NS
Smoking
Never smoked (baseline)
Past smoker 0.620 1.859 (0.44, 7.81) NS
Current smoker 1.342 3.829 (0.94, 15.53) NS
Smoking (pack/year) 0.008 1.008 (1.00, 1.01) .045
Race
White (baseline)
Nonwhite 0.081 1.085 (0.65, 1.81) NS
ABI* –0.252 0.778 (0.71, 0.85) .0005
Pulse pressure –0.003 0.997 (0.99, 1.01) NS
Systolic pressure –0.006 0.994 (0.98, 1.00) NS
Diastolic pressure –0.008 0.992 (0.97, 1.01) NS
Hypertension
No hypertension (baseline)
Hypertension, no drug therapy 0.0399 1.490 (0.77, 2.87) NS
Hypertension, drug therapy –0.360 0.698 (0.47, 1.04) NS
Diabetes
No diabetes (baseline)
Diet-controlled –0.950 0.367 (0.16, 0.96) .039
Oral-hypoglycemic therapy 0.178 1.195 (0.63, 2.26) NS
Insulin therapy 0.590 1.803 (0.71, 1.81) .0202
Angina –0.322 0.725 (0.43, 1.22) NS
Previous myocardial infarction –0.253 0.776 (0.52, 1.17) NS
Previous CVA 0.126 1.134 (0.71, 1.81) NS
*β and RR are shown for a 0.1-unit increase in ABI.
NS, Not statistically significant; CVA, cerebrovascular accident.
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were independent predictors of both IU and IRP (Tables
IV and V). The smoking variable did not retain its predic-
tive value for IRP in the final multivariate model. Fig 2
depicts relevant Kaplan-Meier curves for IRP and IU,
stratified by the presence of diabetes requiring medication
and baseline ABI. An arbitrary cutoff for ABI (0.5) was
used to generate these curves. However, the effect of ABI
was observable across its entire range, as indicated by the
risk ratios shown in Table IV and V.
We have used our model parameters (Tables IV and V)
and raw data to calculate the predicted absolute 5-year risk
of developing IU and IRP (Fig 3). This contrasts with the
RR ratios determined from the proportional hazards
analysis. To perform these calculations, we used the actual
5-year incidence of development of these outcomes in a
reference subgroup of patients not having diabetes and
having ABI between 0.45 and 0.54 and then applied the
RR multipliers shown in Tables IV and V.
DISCUSSION
This study represents one of the largest and longest
analyses of the natural history of intermittent claudica-
Fig 2. Kaplan-Meier curves for both IRP and IU outcomes stratified by the presence of diabetes requiring medication
(DM) and baseline ABI.




tion. Understanding its natural history is crucial to mak-
ing clinical decisions, such as whether surgical revascular-
ization is needed. In comparison with older, larger studies
of patients with claudication, a strength of this current
analysis is that patients were identified with both clinical
and noninvasive criteria; thus, we avoided including
patients with nonvascular leg pain. Our noninvasive crite-
ria for diagnosing claudication are consistent with those of
several other studies.11-13
Our previous work10 documented a high mortality
rate among patients with claudication (about 12% annual-
ized risk of death). We found four key predictive risk fac-
tors for mortality, namely older age, lower ABI, stroke,
and diabetes requiring medication. In the current work,
we found that the 10-year cumulative risk of developing
IRP is roughly 30%. The 10-year risk of developing IU is
about 23%. We also found statistically significant but small
annual reductions in ABI (0.014 units/year) and WalkDist
(9.2 yards/year). In addition, we measured low cumula-
tive rates of amputation (<10% at 10 years). Overall, our
data support the concept that claudication is associated
with a high rate of mortality but relatively benign lower-
extremity outcomes among patients with claudication.
Our data are consistent with previous natural history
studies. Even though atherosclerosis is pathologically a
progressive process, large studies suggest that claudication
is a surprisingly benign clinical entity with respect to
lower-extremity outcomes.11,14 The Basle study docu-
mented angiographic disease progression in 63% of
patients 5 years after the initial diagnosis.15 However,
activity-limiting claudication still did not develop in 66%
of those who survived after 5 years. In general, studies
during the last 40 years suggest that only about a quarter
of patients with intermittent claudication will ever deteri-
orate, most frequently during the first year of the diagno-
sis. Thereafter, deterioration is 2% to 3% annually.8,11
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Table III. Univariate analysis: IU
Variable β RR (CI) P
Age (y) –0.009 0.991 (0.97, 1.01) NS
Smoking
Never smoked (baseline)
Past smoker –0.547 0.579 (0.32, 1.06) NS
Current smoker –0.589 0.555 (0.31, 1.06) NS
Smoking (pack/year) 0.005 1.005 (1.00, 1.01) NS
Race
White (baseline)
Nonwhite –0.205 0.815 (0.50, 1.33) NS
ABI* –0.217 0.805 (0.74, 0.87) .0005
Pulse pressure 0.005 1.005 (1.00, 1.01) NS
Systolic pressure –0.004 0.996 (0.99, 1.00) NS
Diastolic pressure –0.018 0.982 (0.97, 1.00) NS
Hypertension
No hypertension (baseline)
Hypertension, no drug therapy –0.0546 0.579 (0.26, 1.32) NS
Hypertension, no drug therapy –0.248 0.780 (0.57, 1.08) NS
Diabetes
No diabetes (baseline)
Diet-controlled 0.749 2.114 (1.31, 3.41) NS
Oral-hypoglycemic therapy 0.992 2.698 (1.62, 4.50) .0005
Insulin therapy 1.470 4.350 (3.11, 6.09) .0005
Angina –0.167 0.846 (0.55, 1.29) NS
Previous myocardial infaction –0.368 0.692 (0.48, 0.99) NS
Previous CVA 0.197 1.218 (0.82, 1.81) NS
*β and RR are shown for a 0.1-unit increase in ABI.
NS, Not statistically significant; CVA, cerebrovascular accident.
Symptomatic CAD is defined as the presence of either angina or prior myocardial infarction.
Table IV. Multivariate model: IRP
Variable β RR (CI) P
DM 0.551 1.735 (1.19, 2.53) .004
ABI* –0.238 0.788 (0.72, 0.86) .001
Smoking (pack/years) NS
*β and RR are shown for a 0.1-unit increase in ABI.
DM, Diabetes requiring medication; NS, not statistically significant.
Stabilization of symptoms may occur secondary to collat-
eral development, metabolic adaptation of ischemic mus-
cle, or gait alteration favoring nonischemic muscle
groups.11 Reported major amputation rates of 7% during
a 5-year period and 12% during a 10-year period are based
on several population studies.11 However, recent studies
suggest that major amputations are relatively rare in these
patients, with only 1% to 3.3% of patients needing major
amputation during a 5-year period.11 In addition, two
large population-based studies found that less than 2% of
patients with peripheral arterial disease required major
amputation.18,19
The revascularization rate at our VA Medical Center,
18% cumulative frequency at 10 years, is at the higher end
of the range reported in the literature. The reported pro-
portion of patients who will ultimately require operative
intervention varies in the literature from 3% to 22%,
depending largely on the severity of the claudication of the
patient enrolled in the study.16,17 Thus, the lower figures
are likely the truer reflection of what happens to all
patients with claudication. Our relatively high revascular-
ization rate likely reflects the fact that we studied patients
with symptoms severe enough to warrant referral to a vas-
cular laboratory.
Risk factors for the progression of claudication have
been reported in many cohort analyses.11 For disease pro-
gression, the reported risk factors include smoking, dia-
betes, and ABI.11 In our analysis, the development of both
IU and IRP was associated with diabetes and lower ABI.
Although pack-years of smoking was associated with
development of IRP in univariate analysis, it did not play
a significant role when other factors were considered in
the multivariate analysis. In this case, the issue may simply
be that large numbers of our study group (94%) were cur-
rent or past smokers. The small number of nonsmokers
may have made it difficult to determine the true predictive
value of smoking.
The importance of diabetes and its role in disease pro-
gression has been previously demonstrated.5-9 We found
that diet-controlled diabetes was not a significant predic-
tor; however, diabetes that required either oral or insulin
therapy was a strong predictor of the development of these
outcomes. Diabetes in patients with peripheral arterial dis-
ease tends to portend a more aggressive course, with early
large vessel involvement coupled with microangiopathy.
McDaniel and Cronenwett20 showed that these patients
had a 35% risk of sudden ischemia and a 21% risk of ampu-
tation, compared with nondiabetic patients with claudica-
tion. This is consistent with our analysis, which suggests
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that diabetic patients with claudication have a 2.9-fold
increased risk for development of IU and a 1.7-fold
increased risk for development of IRP as compared with
nondiabetic patients.
In our analysis, ABI was the strongest predictor for
progression to IU and IRP. That is, the lower the ABI in
a given patient, the higher the risk that patient had of
developing limb-threatening ischemia. In Dormandy and
Murray’s6 analysis of 1969 patients with claudication, the
most significant predictor of disease deterioration was an
ABI of less than 0.5 on presentation with a risk ratio of
2.3. In the current study, we analyzed ABI as a continu-
ous variable. For IRP, the risk ratio for ABI is 1.25 for a
0.1 decrease in ABI. Likewise, for IU, the risk ratio for
ABI is 1.21 for a 0.1 decrease in ABI.
A limitation of this and other hospital laboratory–
based studies is the selection bias that may occur at multi-
ple levels. Only a subset of patients with claudication will
typically be referred to the vascular laboratory in the first
place. Furthermore, despite our efforts to schedule every
patient to return for follow-up regardless of clinical status,
inevitably some patients fail to return. The net effect of
this winnowing of patients is probably an over-representa-
tion of patients with worse and/or more progressive clau-
dication. A further important limitation of our study
population is the lack of female patients. This is virtually
inevitable, given the setting of the study (VA hospital). In
addition, our study included few Hispanic patients because
of the makeup of the veteran population in the western
Pennsylvania region. In other respects, however, the
demographics and clinical characteristics of our study pop-
ulation (Table I) are not much different from those seen in
other vascular laboratories. Female patients with claudica-
tion are likely to have a natural history different from that
of male patients. Therefore, our results should only be
extrapolated to other male patients with claudication of
sufficient severity to be referred to a noninvasive vascular
laboratory.
Even though the typical patient with claudication has
a relatively benign prognosis with respect to lower-
extremity outcomes, our data allow us to identify a subset
of patients (diabetics with ABI <0.3) having a substan-
tially elevated risk of adverse limb events (Fig 3). This
raises the question of whether such patients are better
served with early revascularization rather than waiting for
the development of IU or IRP. Such a question can only
be answered by a randomized trial, and we are currently
examining the feasibility of such a trial. In the meantime,
we suggest that the threshold for offering surgical revas-
Table V. Multivariate model: IU
Variable β RR (CI) P
DM 1.076 2.932 (2.12, 4.06) .001
ABI* -0.183 0.833 (0.77, 0.90) .001
*β and RR are shown for a 0.1-unit increase in ABI.
DM, Diabetes requiring medication.
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cularization to diabetic patients with claudication with
reduced ABIs should be lower than for other patients
with claudication, as long as other important factors (such
as medical risk factors and availability of conduit) are
equal.
CONCLUSION
This prospectively followed cohort of male veteran
patients with claudication with long-term national follow-
up is one of the largest and longest of its kind. We docu-
mented an average rate of ABI decline of 0.014 per year
and a decline in WalkDist of 9.2 yards per year. Two clin-
ical factors, ABI and diabetes requiring medication, were
found to predict risk of IRP and IU. Our findings may be
useful in predicting the clinical course of claudication and
in making informed decisions about patient selection for
surgical intervention.
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Dr Robert B. Patterson (Providence, RI). Thank you, Dr
Brener and Dr Walsh, members and guests.
Dr Johnnides, I’d like to compliment you on a very nicely
presented paper. This paper represents a reevaluation of the data
that were presented to the SVS-AAVS in Toronto last spring, uti-
lizing the endpoints of ischemic rest pain and ischemic ulceration
rather than death and amputation.
Reading the manuscripts together raises some questions, per-
petuates some weaknesses, and adds little to our corporate knowl-
edge of claudication. The reported cohort has dropped from
2777 to 1244 patients. By requiring three vascular lab studies 2
years apart, are you selecting a biased cohort? The patients lost to
follow-up may have symptom stabilization or improvement and
not return for further clinic and lab visits. Or conversely, they may
have sought care outside the VA system for more advanced vas-
cular disease.
Where are the life tables and error bars to support 12-year
validity? Mean follow-up of 45 months is a far cry from 12 years.
How many patients actually had 12 years of follow-up? Did they
also represent the most symptomatic and were thus more prone
to return?
If ischemic ulceration and ischemic rest pain are considered
limb-threatening endpoints, why did only 18% of the patients go
to surgery when 23% and 30% developed limb-threatening symp-
toms? And if surgery was done primarily for claudication, as your
senior author stated in his discussion in Toronto, how do you
manage limb-threatened patients?
ABI decline was 0.14 per year. What does this mean when
the standard deviation for ABI is plus or minus 0.10? Where is
the life table or graph with error bars?
Self-reported walking distances, as you’ve already alluded to,
without a validated instrument such as the walking impairment
questionnaire, is notoriously unreliable. The decline in walking
distance self-reported of 9 yards per year could be accounted by
many factors. And I suspect an elderly population without clau-
dication may experience a similar decrement.
With diabetes as an independent risk factor, how did you dif-
ferentiate ischemic rest pain and ulceration from neuropathic
pain and ulceration? Does this account for the disparity of symp-
tom progression and revascularization?
The authors suggest the findings in this study will help deter-
mine the need for revascularization. Do they have any data to sug-
gest that intervention in claudicants prior to the onset of
limb-threatening symptoms alters the natural history with regard
to limb loss and mortality? How about therapies directed toward
relief of the claudication symptoms themselves? Our challenge
today is not to demonstrate once again that untreated claudica-
tion infrequently leads to limb-threatening symptoms, but to
DISCUSSION
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explore therapies that improve the lives of patients who are
affected by the physical and social debilitation of claudication
itself.
Thank you.
Dr Christopher Johnnides. I’d like to thank Dr Patterson for
those comments. Looking at the list, I’ll try to go one by one.
Is the cohort biased in the sense that we had patients go out
to 12 years? If I understand the question correctly, are those
patients likely to be more sick? I guess you could say that. The
patients that we have had a range of follow-up. The longest did
go out to 12 years, although all did not go out to 12 years. But
when we analyze the data, we can generate useful information
using Kaplan-Meier proportional Cox hazard methods based
upon a range of ABIs or the presence or absence of diabetes.
The surgical indications; there is a disparity from the prior
paper, if I understand your point correctly again, although the
rate of revascularization in the February issue was 18%, and we
have ischemic ulceration, ischemic rest pain for 30% here, which
are usually operative indications. You also have to look at the rate
of amputation on the first paper, which was approximately 10% at
10 years. I don’t think we can get absolute agreement with num-
bers because you are going to lose some patients that do not want
to have surgery or who die in the follow-up.
As far as ABI loss of 0.014 per year, and in terms of the error
bars, some of the graphs I included, you may have noticed that
some of the lines are truncated, that they didn’t go out to all 12
years. We did it that way just to present a little bit more manage-
able graph. We presented those lines only if the error was within
10% of the mean. If it fell outside of 10%, then we didn’t include
that up to 12 years. We certainly can go back and include the
error bars in those graphs.
The walking impairment questionnaire, again, as I pointed to
in my talk, the more state-of-the-art way of identifying walking dis-
tance data would be treadmills, but I think that the average clini-
cian in general uses information on self-reported walking distance
versus treadmill data, so I still think this information is useful.
And Dr Patterson makes a good point in terms of the relative
contribution of diabetes to ischemic ulceration. The greatly
increased contribution, particularly in ischemic ulceration, proba-
bly is due to neuropathic and microvessel disease, and we didn’t
separate out for those two entities.
And how does this affect selection for surgery, how about
treatment for claudication?
Dr Patterson raises a valid point. Some patients are going to
stabilize and drop out and not be subject to follow-up. We col-
lected these data as part of a prospective study to evaluate these
patients in a research setting. We instructed these patients to follow
up at 6-month and 12-month intervals based upon their clinical
symptoms. Obviously we can only report data on those patients
that did follow up, and it’s logical to assume that those patients that
don’t follow up probably either died or the disease got better. So
I’m not sure how we can improve upon that criticism.
Dr Satish C. Muluk. I’d just like to take a chance to add on
to some of Chris’s comments. I thought he did a fine job in
responding to Dr Patterson’s very insightful questions. I just have
a few additions to make.
I think in terms of the issue of the biased cohort, perhaps the
most important issue in terms of the validity of the data set, it’s
important to keep in mind that this is not simply a retrospective
review of patients who just happened to come to the vascular lab.
This was part of a prospective strategy initiated at our VA many
years ago to bring patients routinely back regardless of their clin-
ical situation, so that they were brought back with a prospective
idea toward collecting data for future research and investigation.
And so, although there is always the possibility of a biased
cohort, I would say that it is as close as one can get to following
a large number of patients. Certainly if patients elected not to
come back or moved from the area or died, there was not much
that could be done. But this was not simply a retrospective review
of data that was collected for other purposes.
The other issue, in terms of the error bars which Dr
Patterson brought up, I think Chris did answer. But to empha-
size, in order to make the figures manageable, we intentionally
did not show the error bars. But the curves are limited to the data
point, the time point, at which the standard error of the mean
exceeds 10% of the survival distribution function, which is a fairly
standard way of limiting the Kaplan-Meier curves and making the
graphs a little more meaningful.
The other issues I thought were already answered, and I’ll
try not to be redundant therefore.
Dr Linda Harris (Buffalo, NY). I enjoyed your paper. I have
a couple questions.
The first is since you found diabetes to be so important in
the progression of disease, did you monitor how well the diabetes
was controlled? Is there any evaluation of their hemoglobin A1c
or any idea how well controlled their diabetes was, and did that
impact their progression of disease?
Two, how did you treat the claudicants? Were they placed on
smoking cessation programs, exercise protocols, or any medical
management such as Pletal or Trental? And if you did those, how
did those impact the progression of disease?
Dr Johnnides. Thank you for your comments.
We did not track hemoglobin A1c’s or strict control dia-
betes. What we did is we divided the group into three groups, as
I had stated—those without diabetes, those that were orally con-
trolled, and those that were controlled with insulin. That could
be worth looking at. Although I think it doesn’t detract from the
data, that those patients that we assumed would have worse dia-
betes, those that require medication, did worse than those that
didn’t require medication.
In answer to your second question, no, we did not look at
the effect of medical treatment on the progression of disease in
our population. That’s something we could do, but it just wasn’t
included in this database.
Dr Daniel B. Walsh (Lebanon, NH). I wonder if I might ask,
given all the variables you did look at, I’m interested that you
didn’t look at renal failure. And I wonder if you have other data
or just some anecdotal knowledge to answer the question about
the impact of renal failure on claudication.
Dr Johnnides. Not for this study. Basically the demographic
characteristics I listed were the main characteristics. As far as
anecdotal knowledge, I wouldn’t be able to venture a guess.
Dr Bruce J. Brener (Millburn, NJ). Just focus on that ques-
tion about bias again. The striking thing about your paper was
the very large number of patients that developed ischemic rest
pain and ulceration.
Dr Johnnides. Certainly. And I think we have to keep in
mind, and this is why I pointed it out, the two glaring character-
istics in our demographic data were that 100% were male and
94% smoked. I think that if you compare these to some of the
prior studies in non-VA populations, there were slightly lower
incidences. I think that reflects the fact that there were more
women and fewer smokers probably in those populations.
Dr Muluk. I would like to make two additional comments.
One is that the nature of referral to a vascular laboratory
does imply a certain degree of clinical severity. There must have
been some reason for the patient to have been initially referred.
So there is a bias in that respect. And it is quite conceivable that
the average claudicant will be less ill and perhaps less prone to
develop these problems. I don’t know of any good way to get
around that problem because it boils down to what we’re capa-
ble of studying.
The second issue about the neuropathic pain is that all of
these patients, in order to have a diagnosis of rest pain, had to
indicate that their pain was improved with dependency in the
hope of separating ischemic from neuropathic pain. Obviously,
the ulceration question is a little more difficult. If someone with
an ABI, say, of 0.7 were to develop an ulcer and had diabetes,
there is no question that neuropathy is a contributor. But I think
we all recognize in those patients that there is a combination of
factors—neuropathy, microvascular disease, and ischemia from
major vascular occlusive disease.
Dr Michael P. Lilly (Baltimore, Md). I agree with your con-
clusion that because such a large proportion of your population
are smokers you cannot draw any distinctions between smokers
and nonsmokers.
However, a number of studies looking at large groups of
claudicants and people with lower-extremity occlusive disease has
shown that there is a strong relationship between progression of
lower-extremity atherosclerosis and cumulative pack-years 
of smoking. Have you taken advantage of the large proportion of
smokers in your study to stratify your data based on total pack-
years smoking or perhaps examine the natural history of those
who have actually quit?
It might be that there is a cohort of claudicants with a differ-
ent natural history of their disease. That would be a very useful
additional bit of information that could come out of this data set.
Dr Johnnides. Thank you for your comments, and I agree.
Just one point that I would like to make, and I didn’t include it
in the slides, is that we did stratify, as I said, our smokers into
those patients that currently smoked and had a history of smok-
ing. There was no difference between significance in either group.
That’s why we lumped them together.
But I agree, I think that if we could get a larger cohort of the
VA population that didn’t smoke, we could definitely get some
more useful information, especially in relation to those patients
that stopped smoking and the supposed beneficial effect on the
progression of disease.
Dr Brener. Did you separate patients with aortoiliac disease
from femoropopliteal disease from combined disease? And do you
think there is a different prognosis associated with the location of
the disease?
Dr Johnnides. We did not separate in this paper, no. I think
that people with more distal disease are thought to do worse, but
actually we are looking at that in another paper we’re preparing,
the differences in proximal versus distal disease.
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